# Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder

> **NCT01696617** · PHASE4 · COMPLETED · sponsor: **Seoul National University Hospital** · enrollment: 46 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Aripiprazole 6-week group
- **DRUG:** Aripiprazole 8-week group

## Key facts

- **NCT ID:** NCT01696617
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-10
- **Primary completion:** 2016-12
- **Final completion:** 2019-02
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2019-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01696617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01696617, "Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01696617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*